Watch The Indian Respiratory Space: Cipla, GSK At Work
This article was originally published in Scrip
Executive Summary
Competition in the fast growing Indian respiratory products market looks set to intensify with key players and traditional rivals, Cipla and GlaxoSmithKline, each outlining distinct new initiatives in the segment.
You may also be interested in...
Amid Pharma ‘Landmarks’ Cipla Develops Tenofovir Prodrug
Cipla’s chair Dr Yusuf Hamied highlighted a series of ‘landmarks’ along the company’s journey at its recent annual general meeting and also indicated that the firm’s tenofovir prodrug, currently in early stage development, could potentially challenge TAF.
Nucala Among Flurry Of New Respiratory Products On Indian Horizon
Novel asthma/COPD drugs, including GlaxoSmithKline’s biologic therapy Nucala, are on the horizon in India, set to expand treatment options in the competitive segment. But pricing is expected to be key in pushing uptake, and health care delivery in asthma/COPD in India remains rather sub-optimal, notwithstanding the interest around new launches.
Interview: GSK India's Playbook For Vaccines Dominance
Deft pricing and effective physician engagement appear to have helped shape GSK's sustained dominance in the Indian self-pay vaccines market. GSK Pharmaceuticals India managing director, Annaswamy Vaidheesh, takes Scrip through some of the strategies at play including the sharp recalibration in the price of Synflorix and how the British multinational is harnessing digital technology to stay "close" to its customers.